Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy

According to the EPOC study, chemotherapy could improve 5-year disease-free survival of stage IV colon cancer patients by 8.1%. However, more molecular biomarkers are required to identify patients who need neoadjuvant chemotherapy. DENND2D expression was evaluated by immunohistochemistry in 181 stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Wen-juan, Chen, Yukun, Peng, Jian-hong, Tang, Chaoming, Zhang, Ling, Liu, Min, Hu, Shanshan, Xu, Haineng, Tan, Hua, Gu, Yangkui, Pan, Zhi-zhong, Chen, Gong, Zhou, Zhong-guo, Zhang, Rong-xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076603/
https://www.ncbi.nlm.nih.gov/pubmed/35523764
http://dx.doi.org/10.1038/s41419-022-04885-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076603/
https://www.ncbi.nlm.nih.gov/pubmed/35523764
http://dx.doi.org/10.1038/s41419-022-04885-8

Ejemplares similares